Ultrastructural analysis of breast cancer patient-derived organoids.
Breast cancer
Patient-derived organoids
Transmission electron microscopy
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
10 Aug 2021
10 Aug 2021
Historique:
received:
02
04
2021
accepted:
03
08
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Breast cancer Patient Derived Organoids (PDO) have been demonstrated to be a reliable model to study cancer that promised to replace and reduce the use of animals in pre-clinical research. They displayed concordance with the tissue of origin, resuming its heterogenicity and representing a good platform to develop approaches of personalized medicines. Although obtain PDOs from mammary tumour, was a very challenging process, several ongoing studies evaluated them as a platform to study efficacy, sensitivity and specificity of new drugs and exploited them in personalized medicine. Despite tissue organization represented a crucial point to evaluate in a 3-dimensional model, since it could influence drug penetration, morphology of breast cancer PDOs has not been analysed yet. Here, we proposed a complete ultrastructural analysis of breast PDOs obtained from tumour and healthy tissues to evaluate how typical structures observed in mammary gland were resumed in this model. 81 samples of mammary tissue (healthy or tumour) resulting from surgical resections have been processed to obtain PDO. The resulting PDOs embedded in matrigel drop have been processed for transmission electron microscopy and analysed. A comparison between ones from healthy and ones from cancerous tissue has been performed and PDOs derived from tumour tissue have been stratified according to their histological and molecular subtype. The morphological analysis performed on 81 PDO revealed an organized structure rich in Golgi, secretion granules and mitochondria, which was typical of cells with a strong secretory activity and active metabolism. The presence of desmosomes, inter and intracellular lumens and of microvilli and interdigitations signified a precise tissue-organization. Each PDO has been classified based on whether or not it possessed (i) peripheral ridges in mitochondria, (ii) intracellular lumens, (iii) intercellular lumens, (iv) micro-vesicles, (v) open desmosomes, (vi) cell debris, (vii) polylobed nuclei, (viii) lysosomes and (ix) secretion granules, in order to identify features coupled with the cancerous state or with a specific histological or molecular subtype. Here we have demonstrated the suitability of breast cancer PDO as 3-dimensional model of mammary tissue. Besides, some structural features characterizing cancerous PDO have been observed, identifying the presence of distinctive traits.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer Patient Derived Organoids (PDO) have been demonstrated to be a reliable model to study cancer that promised to replace and reduce the use of animals in pre-clinical research. They displayed concordance with the tissue of origin, resuming its heterogenicity and representing a good platform to develop approaches of personalized medicines. Although obtain PDOs from mammary tumour, was a very challenging process, several ongoing studies evaluated them as a platform to study efficacy, sensitivity and specificity of new drugs and exploited them in personalized medicine. Despite tissue organization represented a crucial point to evaluate in a 3-dimensional model, since it could influence drug penetration, morphology of breast cancer PDOs has not been analysed yet. Here, we proposed a complete ultrastructural analysis of breast PDOs obtained from tumour and healthy tissues to evaluate how typical structures observed in mammary gland were resumed in this model.
METHODS
METHODS
81 samples of mammary tissue (healthy or tumour) resulting from surgical resections have been processed to obtain PDO. The resulting PDOs embedded in matrigel drop have been processed for transmission electron microscopy and analysed. A comparison between ones from healthy and ones from cancerous tissue has been performed and PDOs derived from tumour tissue have been stratified according to their histological and molecular subtype.
RESULT
RESULTS
The morphological analysis performed on 81 PDO revealed an organized structure rich in Golgi, secretion granules and mitochondria, which was typical of cells with a strong secretory activity and active metabolism. The presence of desmosomes, inter and intracellular lumens and of microvilli and interdigitations signified a precise tissue-organization. Each PDO has been classified based on whether or not it possessed (i) peripheral ridges in mitochondria, (ii) intracellular lumens, (iii) intercellular lumens, (iv) micro-vesicles, (v) open desmosomes, (vi) cell debris, (vii) polylobed nuclei, (viii) lysosomes and (ix) secretion granules, in order to identify features coupled with the cancerous state or with a specific histological or molecular subtype.
CONCLUSION
CONCLUSIONS
Here we have demonstrated the suitability of breast cancer PDO as 3-dimensional model of mammary tissue. Besides, some structural features characterizing cancerous PDO have been observed, identifying the presence of distinctive traits.
Identifiants
pubmed: 34376194
doi: 10.1186/s12935-021-02135-z
pii: 10.1186/s12935-021-02135-z
pmc: PMC8353820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
423Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 2017E3A2NR (Prin 2017)
Informations de copyright
© 2021. The Author(s).
Références
Nat Cell Biol. 2016 Mar;18(3):246-54
pubmed: 26911908
Br J Cancer. 1964 Dec;18:682-5
pubmed: 14264932
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Am J Clin Pathol. 1976 Aug;66(2):291-375
pubmed: 181979
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Oncogene. 2011 Jan 13;30(2):127-38
pubmed: 20890307
Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G257-G265
pubmed: 28126704
J Surg Case Rep. 2019 Jun 14;2019(6):rjz182
pubmed: 31214320
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 2017 Dec;23(12):1424-1435
pubmed: 29131160
Cancer. 1972 Apr;29(4):987-95
pubmed: 4335981
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Mol Clin Oncol. 2018 Apr;8(4):587-591
pubmed: 29556390
Cancer Cell Int. 2020 Mar 18;20:86
pubmed: 32206037
Cancer Res. 2014 Sep 15;74(18):5184-94
pubmed: 25100563
Case Rep Pathol. 2020 Aug 28;2020:4806342
pubmed: 32908759
J Natl Cancer Inst. 2020 May 1;112(5):540-544
pubmed: 31589320
Cancer Res. 1977 Jul;37(7 Pt 1):2004-14
pubmed: 140761
Med Mol Morphol. 2005 Dec;38(4):216-24
pubmed: 16378230
Annu Rev Pathol. 2020 Jan 24;15:211-234
pubmed: 31550983
Nat Rev Genet. 2018 Nov;19(11):671-687
pubmed: 30228295
Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23
pubmed: 23456611
Biol Proced Online. 2019 Jun 15;21:12
pubmed: 31223292